Hot Features
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the trea... Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.64 | -14.5124716553 | 4.41 | 4.5899 | 3.78 | 44688 | 4.2473262 | CS |
| 4 | -1.4 | -27.079303675 | 5.17 | 5.2099 | 3.78 | 28431 | 4.52605797 | CS |
| 12 | -3.92 | -50.9752925878 | 7.69 | 7.69 | 3.78 | 28608 | 5.2184869 | CS |
| 26 | 3.28 | 669.387755102 | 0.49 | 8.055 | 0.2163 | 793852 | 0.56405323 | CS |
| 52 | 3.29 | 685.416666667 | 0.48 | 8.055 | 0.1853 | 9117770 | 0.99596047 | CS |
| 156 | -2.18 | -36.6386554622 | 5.95 | 11.44 | 0.1853 | 3233398 | 1.10066196 | CS |
| 260 | -2.18 | -36.6386554622 | 5.95 | 11.44 | 0.1853 | 3233398 | 1.10066196 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.